Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 25.41% is 158% above its 5-year average of 9.83%, near the high end of its 5-year range (-11.32%–25.41%).
As of the fiscal period ended Wednesday, December 31, 2025. 96.60% above its 12-month average of 12.92%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
25.41%
RETURN ON EQUITY (ROE) AVG TTM
12.92%
RETURN ON EQUITY (ROE) AVG 3Y
11.29%
RETURN ON EQUITY (ROE) AVG 5Y
9.83%
RETURN ON EQUITY (ROE) AVG 10Y
8.31%
RETURN ON EQUITY (ROE) AVG 15Y
17.00%
RETURN ON EQUITY (ROE) AVG 20Y
29.48%
CURRENT VS TTM AVG
+96.60%
CURRENT VS 3Y AVG
+125.07%
CURRENT VS 5Y AVG
+158.41%
CURRENT VS 10Y AVG
+205.94%
CURRENT VS 15Y AVG
+49.43%
CURRENT VS 20Y AVG
-13.80%
SECTOR MEDIAN · HEALTHCARE
10.61%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+139.49%
vs the sector median at left
Incyte Corporation
Market Cap
$24.28B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$24.72B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$23.16B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$25.74B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$22.68B
Return on Equity (ROE)
10.89%
TTM Avg
10.12%
3Y Avg
7.00%
5Y Avg
7.00%
Market Cap
$26.03B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$26.07B
Return on Equity (ROE)
1.09%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$22.32B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$22.03B
Return on Equity (ROE)
21.82%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $24.28B | 25.41% | 12.92% | 11.29% | 9.83% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 18.89% | 16.95% | 19.08% | 20.56% |
| BioNTech SE (BNTX)vs › | $23.16B | -6.79% | -4.55% | 10.63% | 21.70% |
| Labcorp Holdings Inc. (LH)vs › | $25.74B | 11.65% | 9.71% | 9.35% | 12.84% |
| STERIS plc (STE)vs › | $22.68B | 10.89% | 10.12% | 7.00% | 7.00% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.03B | 14.13% | 13.34% | 14.07% | 18.07% |
| Waters Corporation (WAT)vs › | $26.07B | 1.09% | 29.98% | 64.02% | 111.55% |
| Moderna, Inc. (MRNA)vs › | $22.32B | -46.61% | -32.64% | -13.90% | 0.25% |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 21.82% | 18.68% | 17.25% | 16.03% |
| Viatris Inc. (VTRS)vs › | $20.55B | -2.02% | -13.64% | -4.29% | -4.38% |
ROE
25.4%
ROA
20.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 24.90% |
| 2024-12-31 | 0.95% |
| 2023-12-31 | 11.51% |
| 2022-12-31 | 7.80% |
| 2021-12-31 | 25.16% |
| 2020-12-31 | -11.32% |
| 2019-12-31 | 17.20% |
| 2018-12-31 | 5.69% |
| 2017-12-31 | -19.20% |
| 2016-12-31 | 24.85% |
| 2015-12-31 | 3.82% |
| 2014-12-31 | 59.39% |
| 2013-12-31 | 43.06% |
| 2012-12-31 | 25.33% |
| 2011-12-31 | 82.15% |
| 2010-12-31 | 35.93% |
| 2009-12-31 | 206.94% |
| 2008-12-31 | 81.05% |
| 2007-12-31 | 54.47% |
| 2006-12-31 | 87.35% |
| 2005-12-31 | 531.23% |
| 2004-12-31 | -209.91% |
| 2003-12-31 | -107.86% |
| 2002-12-31 | -45.26% |
| 2001-12-31 | -41.63% |
| 2000-12-31 | -4.78% |
| 1999-12-31 | -15.74% |
| 1998-12-31 | 1.95% |
| 1997-12-31 | 4.73% |
| 1996-12-31 | -15.04% |
